Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study.

Castillo JJ, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre TA, Chavez JC, Shain KH, Issa S, Palomba ML, Pasvolsky O, Simpson D, Talaulikar D, Tam CS, Tedeschi A, Ansell SM, Nayak L, Treon SP.

Blood. 2019 Jan 24;133(4):299-305. doi: 10.1182/blood-2018-10-879593. Epub 2018 Dec 6.

PMID:
30523119
2.

Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib.

Cheng MP, Kusztos AE, Gustine JN, Dryden-Peterson SL, Dubeau TE, Woolley AE, Hammond SP, Baden LR, Treon SP, Castillo JJ, Issa NC.

Br J Haematol. 2018 Nov 20. doi: 10.1111/bjh.15627. [Epub ahead of print] No abstract available.

PMID:
30460682
3.

Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study.

Barth P, Castillo JJ, Olszewski AJ.

Cancer. 2019 Feb 15;125(4):550-558. doi: 10.1002/cncr.31853. Epub 2018 Nov 19.

PMID:
30452087
4.

Ibrutinib and Rituximab in Waldenström's Macroglobulinemia.

Olszewski AJ, Castillo JJ.

N Engl J Med. 2018 Nov 15;379(20):1973-4. doi: 10.1056/NEJMc1809505. No abstract available.

PMID:
30439672
5.

Long survival in patients with Waldenström macroglobulinaemia diagnosed at a young age.

Babwah A, Gustine J, Meid K, Dubeau T, Xu L, Yang G, Hunter ZR, Treon SP, Castillo JJ.

Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15634. [Epub ahead of print] No abstract available.

PMID:
30407630
6.

Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.

Hunter ZR, Xu L, Tsakmaklis N, Demos MG, Kofides A, Jimenez C, Chan GG, Chen J, Liu X, Munshi M, Gustine J, Meid K, Patterson CJ, Yang G, Dubeau T, Samur MK, Castillo JJ, Anderson KC, Munshi NC, Treon SP.

Blood Adv. 2018 Nov 13;2(21):2937-2946. doi: 10.1182/bloodadvances.2018022962.

7.

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.

Sklavenitis-Pistofidis R, Capelletti M, Liu CJ, Reidy M, Zavidij O, Huynh D, Henrick P, Savell A, Reyes K, Rivotto B, Bustoros M, Perilla-Glen A, Trippa L, Castillo JJ, Treon SP, Ghobrial IM.

Blood. 2018 Dec 13;132(24):2608-2612. doi: 10.1182/blood-2018-07-863241. Epub 2018 Oct 26. No abstract available.

PMID:
30366921
8.

Different phenotypes of non-classical monocytes associated with systemic inflammation, endothelial alteration and hepatic compromise in patients with dengue.

Naranjo-Gómez JS, Castillo JA, Rojas M, Restrepo BN, Diaz FJ, Velilla PA, Castaño D.

Immunology. 2019 Feb;156(2):147-163. doi: 10.1111/imm.13011. Epub 2018 Nov 8.

PMID:
30315653
9.

Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia.

Bouyssou JM, Liu CJ, Bustoros M, Sklavenitis-Pistofidis R, Aljawai Y, Manier S, Yosef A, Sacco A, Kokubun K, Tsukamoto S, Perilla Glen A, Huynh D, Castillo JJ, Treon SP, Leblond V, Hermine O, Roccaro AM, Ghobrial IM, Capelletti M.

PLoS One. 2018 Oct 4;13(10):e0204589. doi: 10.1371/journal.pone.0204589. eCollection 2018.

10.

Mechanisms of monocyte cell death triggered by dengue virus infection.

Castillo JA, Urcuqui-Inchima S.

Apoptosis. 2018 Dec;23(11-12):576-586. doi: 10.1007/s10495-018-1488-1. Review.

PMID:
30267240
11.

Turing-Hopf patterns on growing domains: The torus and the sphere.

Sánchez-Garduño F, Krause AL, Castillo JA, Padilla P.

J Theor Biol. 2018 Sep 25. pii: S0022-5193(18)30464-8. doi: 10.1016/j.jtbi.2018.09.028. [Epub ahead of print]

PMID:
30266461
12.

Role of Monocytes in the Pathogenesis of Dengue.

Castillo JA, Naranjo JS, Rojas M, Castaño D, Velilla PA.

Arch Immunol Ther Exp (Warsz). 2019 Feb;67(1):27-40. doi: 10.1007/s00005-018-0525-7. Epub 2018 Sep 20. Review.

PMID:
30238127
13.

Waldenström Macroglobulinemia: Lessons Learned from Basic and Clinical Research.

Castillo JJ, Kastritis E, Treon SP.

Hematol Oncol Clin North Am. 2018 Oct;32(5):xiii-xiv. doi: 10.1016/j.hoc.2018.07.001. No abstract available.

PMID:
30190026
14.

Monoclonal Antibodies for Waldenström Macroglobulinemia.

Dominguez A, Kastritis E, Castillo JJ.

Hematol Oncol Clin North Am. 2018 Oct;32(5):841-852. doi: 10.1016/j.hoc.2018.05.010. Epub 2018 Jul 21. Review.

PMID:
30190022
15.

Initial Evaluation of the Patient with Waldenström Macroglobulinemia.

Castillo JJ, Treon SP.

Hematol Oncol Clin North Am. 2018 Oct;32(5):811-820. doi: 10.1016/j.hoc.2018.05.008. Epub 2018 Jul 23. Review.

PMID:
30190019
16.

Genomic Landscape of Waldenström Macroglobulinemia.

Treon SP, Xu L, Liu X, Hunter ZR, Yang G, Castillo JJ.

Hematol Oncol Clin North Am. 2018 Oct;32(5):745-752. doi: 10.1016/j.hoc.2018.05.003. Epub 2018 Jul 25. Review.

PMID:
30190014
17.

TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.

Gustine JN, Tsakmaklis N, Demos MG, Kofides A, Chen JG, Liu X, Munshi M, Guerrera ML, Chan GG, Patterson CJ, Meid K, Dubeau T, Yang G, Hunter ZR, Treon SP, Castillo JJ, Xu L.

Br J Haematol. 2019 Jan;184(2):242-245. doi: 10.1111/bjh.15560. Epub 2018 Sep 5.

PMID:
30183082
18.

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.

Treon SP, Gustine J, Meid K, Yang G, Xu L, Liu X, Demos M, Kofides A, Tsakmaklis N, Chen JG, Munshi M, Chan G, Dubeau T, Raje N, Yee A, O'Donnell E, Hunter ZR, Castillo JJ.

J Clin Oncol. 2018 Sep 20;36(27):2755-2761. doi: 10.1200/JCO.2018.78.6426. Epub 2018 Jul 25.

PMID:
30044692
19.

Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases.

Jurczyszyn A, Davila J, Kortüm KM, Jayabalan DS, Vij R, Fiala M, Milunovic V, Chim CS, Wiśniewska-Piąty K, Waszczuk-Gajda A, Crusoe E, Hajek R, Robak P, Raźny M, Zawirska D, Bittrich M, Nahi H, Liu J, Castillo JJ, Vesole DH.

Leuk Lymphoma. 2018 Jul 22:1-6. doi: 10.1080/10428194.2018.1480766. [Epub ahead of print]

PMID:
30033832
20.

Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case-control study.

Jurczyszyn A, Castillo JJ, Vesole DH, Liu J, Avivi I, Waszczuk-Gajda A, Lech-Maranda E, Gentile M, Mikala G, Guerrero-Garcia T, Suska A, Gertz MA.

Am J Hematol. 2018 Sep;93(9):E238-E241. doi: 10.1002/ajh.25209. Epub 2018 Aug 6. No abstract available.

PMID:
29989240
21.

EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management.

Castillo JJ, Beltran BE, Miranda RN, Young KH, Chavez JC, Sotomayor EM.

Am J Hematol. 2018 Jul;93(7):953-962. doi: 10.1002/ajh.25112.

PMID:
29984868
22.

Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.

Jurczyszyn A, Castillo JJ, Avivi I, Czepiel J, Davila J, Vij R, Fiala MA, Gozzetti A, Grząśko N, Milunovic V, Hus I, Mądry K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Dębski J, Atilla E, Beksac M, Mele G, Sawicki W, Jayabalan D, Charliński G, Gyula Szabo A, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Crusoe E, Hungria V, Richardson P, Laubach J, Guerrero-Garcia T, Liu J, Vesole DH.

Leuk Lymphoma. 2019 Jan;60(1):118-123. doi: 10.1080/10428194.2018.1473574. Epub 2018 Jul 2.

PMID:
29965787
23.

The real world of Waldenström's macroglobulinaemia.

Treon SP, Castillo JJ.

Lancet Haematol. 2018 Jul;5(7):e275-e276. doi: 10.1016/S2352-3026(18)30091-7. No abstract available.

PMID:
29958567
24.

Prevalence and Data Availability of Early Childhood Caries in 193 United Nations Countries, 2007-2017.

El Tantawi M, Folayan MO, Mehaina M, Vukovic A, Castillo JL, Gaffar BO, Arheiam A, Al-Batayneh OB, Kemoli AM, Schroth RJ, Lee GHM.

Am J Public Health. 2018 Aug;108(8):1066-1072. doi: 10.2105/AJPH.2018.304466. Epub 2018 Jun 21.

PMID:
29927650
25.

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.

Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia.

N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1.

26.

Viral lymphomagenesis: beyond the usual suspects.

Castillo JJ.

Br J Haematol. 2018 Sep;182(5):617-618. doi: 10.1111/bjh.15414. Epub 2018 May 29. No abstract available.

PMID:
29808932
27.

Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia.

Castillo JJ, Gustine JN, Meid K, Dubeau TE, Xu L, Yang G, Hunter ZR, Advani R, Palomba L, Treon SP.

Haematologica. 2018 Oct;103(10):e466-e468. doi: 10.3324/haematol.2018.191999. Epub 2018 May 17. No abstract available.

28.

Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with Waldenström Macroglobulinemia.

Castillo JJ, Dubeau T, Kofides A, Demos MG, Tsakmaklis N, Xu L, Hunter ZR, Treon SP.

Am J Hematol. 2018 May 14. doi: 10.1002/ajh.25142. [Epub ahead of print] No abstract available.

PMID:
29756293
29.

True, true unrelated? Coexistence of Waldenström macroglobulinemia and cardiac transthyretin amyloidosis.

Singh A, Geller HI, Alexander KM, Padera RF, Mitchell RN, Dorbala S, Castillo JJ, Falk RH.

Haematologica. 2018 Aug;103(8):e374-e376. doi: 10.3324/haematol.2018.190405. Epub 2018 Apr 19. No abstract available.

30.

Prediabetes in Colombia: Expert Consensus.

López-Jaramillo P, Calderón C, Castillo J, Escobar ID, Melgarejo E, Parra GA.

Colomb Med (Cali). 2017 Dec 30;48(4):191-203. doi: 10.25100/cm.v43i4.3662. Review.

31.

Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia.

Castillo JJ, Meid K, Gustine JN, Dubeau T, Severns P, Hunter ZR, Yang G, Xu L, Treon SP.

Clin Cancer Res. 2018 Jul 15;24(14):3247-3252. doi: 10.1158/1078-0432.CCR-18-0152. Epub 2018 Apr 16.

PMID:
29661775
32.

Basic life support and external defibrillation competences after instruction and at 6 months comparing face-to-face and blended training. Randomised trial.

Castillo J, Gallart A, Rodríguez E, Castillo J, Gomar C.

Nurse Educ Today. 2018 Jun;65:232-238. doi: 10.1016/j.nedt.2018.03.008. Epub 2018 Mar 24.

PMID:
29605787
33.

MYD88 mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4.

Guerrera ML, Tsakmaklis N, Xu L, Yang G, Demos M, Kofides A, Chan GG, Manning RJ, Liu X, Chen JG, Munshi M, Patterson CJ, Castillo JJ, Dubeau T, Gustine J, Carrasco RD, Arcaini L, Varettoni M, Cazzola M, Treon SP, Hunter ZR.

Haematologica. 2018 Sep;103(9):e408-e411. doi: 10.3324/haematol.2018.190181. Epub 2018 Mar 29. No abstract available.

34.

Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia.

Castillo JJ, Gustine JN, Meid K, Dubeau T, Severns P, Xu L, Yang G, Hunter ZR, Treon SP.

Br J Haematol. 2019 Mar;184(6):1011-1014. doi: 10.1111/bjh.15200. Epub 2018 Mar 13. No abstract available.

PMID:
29532913
35.

Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.

Castillo JJ, Guerrero-Garcia T, Baldini F, Tchernonog E, Cartron G, Ninkovic S, Cwynarski K, Dierickx D, Tousseyn T, Lansigan F, Linnik Y, Mogollon R, Navarro JT, Olszewski AJ, Reagan JL, Fedele P, Gilbertson M, Grigoriadis G, Bibas M.

Br J Haematol. 2019 Feb;184(4):679-682. doi: 10.1111/bjh.15156. Epub 2018 Mar 12. No abstract available.

PMID:
29527667
36.

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.

Chen JG, Liu X, Munshi M, Xu L, Tsakmaklis N, Demos MG, Kofides A, Guerrera ML, Chan GG, Patterson CJ, Meid K, Gustine J, Dubeau T, Severns P, Castillo JJ, Hunter ZR, Wang J, Buhrlage SJ, Gray NS, Treon SP, Yang G.

Blood. 2018 May 3;131(18):2047-2059. doi: 10.1182/blood-2017-10-811752. Epub 2018 Mar 1.

PMID:
29496671
37.

The neutrophil-lymphocyte ratio is prognostic in patients with early stage aggressive peripheral T cell lymphoma.

Beltran BE, Castro D, De La Cruz-Vargas JA, Cotrina E, Gallo A, Sotomayor EM, Castillo JJ.

Br J Haematol. 2019 Feb;184(4):650-653. doi: 10.1111/bjh.15141. Epub 2018 Feb 26. No abstract available.

PMID:
29479670
38.

The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma.

Beltrán BE, Paredes S, Cotrina E, Sotomayor EM, Castillo JJ.

Leuk Res. 2018 Apr;67:82-85. doi: 10.1016/j.leukres.2018.02.011. Epub 2018 Feb 19.

PMID:
29477024
39.

Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.

Castillo JJ, Gustine JN, Meid K, Dubeau T, Severns P, Treon SP.

Haematologica. 2018 Jul;103(7):e307-e310. doi: 10.3324/haematol.2017.186908. Epub 2018 Feb 22. No abstract available.

40.

Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia.

Castillo JJ, Gustine JN, Meid K, Dubeau TE, Severns P, Xu L, Yang G, Hunter ZR, Treon SP.

Br J Haematol. 2018 Apr;181(1):77-85. doi: 10.1111/bjh.15148. Epub 2018 Feb 22.

PMID:
29468652
41.

Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia.

Castillo JJ, Gustine JN, Treon SP.

JAMA Oncol. 2018 May 1;4(5):744-745. doi: 10.1001/jamaoncol.2017.0734. No abstract available.

PMID:
29392274
42.

Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.

Jurczyszyn A, Radocha J, Davila J, Fiala MA, Gozzetti A, Grząśko N, Robak P, Hus I, Waszczuk-Gajda A, Guzicka-Kazimierczak R, Atilla E, Mele G, Sawicki W, Jayabalan DS, Charliński G, Szabo AG, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Avivi I, Rodzaj M, Leleu X, Richez V, Knopińska-Posłuszny W, Masternak A, Yee AJ, Barchnicka A, Druzd-Sitek A, Guerrero-Garcia T, Liu J, Vesole DH, Castillo JJ.

Br J Haematol. 2018 Mar;180(6):831-839. doi: 10.1111/bjh.15092. Epub 2018 Jan 7.

PMID:
29315478
43.

What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy.

Treon SP, Castillo JJ.

Blood Adv. 2017 Nov 28;1(25):2486-2490. doi: 10.1182/bloodadvances.2017005637. eCollection 2017 Nov 28.

44.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, Martin T, Neppalli VT, Omel J, Raje N, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shead DA.

J Natl Compr Canc Netw. 2018 Jan;16(1):11-20. doi: 10.6004/jnccn.2018.0002.

PMID:
29295877
45.

Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound.

Gustine JN, Meid K, Dubeau T, Severns P, Hunter ZR, Guang Y, Xu L, Treon SP, Castillo JJ.

Am J Hematol. 2018 Aug;93(4):511-517. doi: 10.1002/ajh.25023. Epub 2018 Jan 25.

PMID:
29280186
46.

Toward personalized treatment in Waldenström macroglobulinemia.

Castillo JJ, Treon SP.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):365-370. doi: 10.1182/asheducation-2017.1.365. Review.

47.

Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia.

Castillo JJ, Gustine JN, Meid K, Xu L, Hunter ZR, Treon SP.

Am J Hematol. 2018 Mar;93(3):E69-E71. doi: 10.1002/ajh.24997. Epub 2017 Dec 23. No abstract available.

48.

MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.

Treon SP, Gustine J, Xu L, Manning RJ, Tsakmaklis N, Demos M, Meid K, Guerrera ML, Munshi M, Chan G, Chen J, Kofides A, Patterson CJ, Yang G, Liu X, Severns P, Dubeau T, Hunter ZR, Castillo JJ.

Br J Haematol. 2018 Feb;180(3):374-380. doi: 10.1111/bjh.15049. Epub 2017 Nov 27.

PMID:
29181840
49.

Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course?

Beltran BE, Quiñones P, Sanchez G, Paredes A, Moises C, Cotrina E, Torres-Cabala CA, Miranda RN, Castillo JJ.

Leuk Lymphoma. 2018 Jul;59(7):1753-1755. doi: 10.1080/10428194.2017.1393666. Epub 2017 Oct 30. No abstract available.

PMID:
29081245
50.

Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base.

Qunaj L, Castillo JJ, Olszewski AJ.

Leuk Lymphoma. 2018 Jun;59(6):1375-1383. doi: 10.1080/10428194.2017.1387912. Epub 2017 Oct 11.

PMID:
29019447

Supplemental Content

Loading ...
Support Center